TY  - JOUR
AU  - Freitag, Martin
AU  - Radtke, Jan Philipp
AU  - Afshar-Oromieh, Ali
AU  - Roethke, Matthias C
AU  - Hadaschik, Boris A
AU  - Gleave, Martin
AU  - Bonekamp, David
AU  - Kopka, Klaus
AU  - Eder, Matthias
AU  - Heusser, Thorsten
AU  - Kachelriess, Marc
AU  - Wieczorek, Kathrin
AU  - Sachpekidis, Christos
AU  - Flechsig, Paul
AU  - Giesel, Frederik
AU  - Hohenfellner, Markus
AU  - Haberkorn, Uwe
AU  - Schlemmer, Heinz-Peter
AU  - Dimitrakopoulou-Strauss, A.
TI  - Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in (68)Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI.
JO  - European journal of nuclear medicine and molecular imaging
VL  - 44
IS  - 5
SN  - 1619-7089
CY  - Heidelberg [u.a.]
PB  - Springer-Verl.
M1  - DKFZ-2017-01024
SP  - 776 - 787
PY  - 2017
AB  - The positron emission tomography (PET) tracer (68)Ga-PSMA-11, targeting the prostate-specific membrane antigen (PSMA), is rapidly excreted into the urinary tract. This leads to significant radioactivity in the bladder, which may limit the PET-detection of local recurrence (LR) of prostate cancer (PC) after radical prostatectomy (RP), developing in close proximity to the bladder. Here, we analyze if there is additional value of multi-parametric magnetic resonance imaging (mpMRI) compared to the (68)Ga-PSMA-11-PET-component of PET/CT or PET/MRI to detect LR.One hundred and nineteen patients with biochemical recurrence after prior RP underwent both hybrid (68)Ga-PSMA-11-PET/CTlow-dose (1 h p.i.) and -PET/MRI (2-3 h p.i.) including a mpMRI protocol of the prostatic bed. The comparison of both methods was restricted to the abdomen with focus on LR (McNemar). Bladder-LR distance and recurrence size were measured in axial T2w-TSE. A logistic regression was performed to determine the influence of these variables on detectability in (68)Ga-PSMA-11-PET. Standardized-uptake-value (SUVmean) quantification of LR was performed.There were 93/119 patients that had at least one pathologic finding. In addition, 18/119 Patients (15.1
KW  - (68Ga)Glu-urea-Lys(Ahx)-HBED-CC (NLM Chemicals)
KW  - Organometallic Compounds (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:27988802
DO  - DOI:10.1007/s00259-016-3594-z
UR  - https://inrepo02.dkfz.de/record/120596
ER  -